Patients are included if they have a histologically confirmed locally advanced or metastatic ccRCC or nccRCC with radiographic disease progression during or following treatment with a PD-1/PD-L1 inhibitor [31]. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.